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Abstract:
Thalassemia disorder is a heterogenous disorder of alpha and beta globin chain production. It results in
destruction of red blood cells leading to hemolytic anemia. Pregnancy complicated by thalassemia is
rare to occur .It can result in pregnancy wastage when uncared for. Pregnant woman with thalassemia
are prone for pre-eclampsia, intra uterine growth restriction, preterm labour and poor reproductive
outcome. A case of pregnancy complicated by beta thalassemia is presented here. She was third gravida
with full term pregnancy with severe anemia with signs of cardiac failure, severe hepatosplenomegaly,
severe intrauterine growth restriction resulting in fetal death. She was treated with urgent blood transfusion
and delivered a fresh still born baby.Her haemoglobin was 4.2 gm%. Her haematological profile showed
reduction in mean corpuscular volume and mean corpuscular haemoglobin.. Although her Hb
electrophoresis showed thalassemia minor trait, there were features in favour of thalassemia intermedia.
Post natal counselling was done to prevent recurrence of intrauterine death due to severe anaemia in
future pregnancies.
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Introduction:
Haemoglobinopathies are the most common genetic
diseases of human race. According to WHO, the world
wide carrier frequency is 4.5% and the affected birth
rate is 2 in 1000 live births[1].
Thalassemia disorders are a diverse group of microcytic
hemolytic anaemias that have deficient synthesis of alpha
or beta globin chains. They occur in individuals of
Mediterranean, Middle Eastern, South East Asian,
African and Asian Indian descent.
Clinical Summary:
A 25 years old 3rd gravida presented with 39 weeks of
gestation with intrauterine fetal demise with severe
anaemia. She was a known case of beta Thalassemia
minor with recurrent fetal wastage.
Figure 1: A Case  of beta Thalassemia  with
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On general examination, there was typical Chipmunk
(Thalassemic) facies, which include depressed nasal
bridge, prominent malar and parietal prominence, flat
forehead and protruding jaw. She had tachycardia with
severe degree of pallor and no icterus. Per abdominal
examination revealed 30 wks gestation with intra uterine
fetal death with good uterine contractions. Severe
hepatosplenomegaly was present. On per vaginal
examination,cervix  was fully dilated.
Patient was diagnosed as Gravida 3, Abortion 2 with
full term gestation with intrauterine fetal death with
severe anaemia with known case of thalassemia trait in
second stage of labour. She delivered a severely growth
restricted dead baby of 1.3 kg  .There were no obvious
congenital anomalies in fetus. Placental weight was 300
gms.  Patient received  three  units of  blood
transfusion.Postnatal period was uneventful. Her
haemoglobin on discharge was 6.3 gm%.
Investigations:
Haemoglobin-4.2 gm%, Blood group-A positive, Total
leucocyte count-4,600 cells/mm3, Differential
leucocyte count-Polymorphs-62%, Lymohocytes-
34%, Eosinophils-1%, Monocytes-3%, Platelet
count-58,000 cells/cubic mm, Reticulocyte count-
2.5%, Prothrombin  time-12 seconds,  Mean
corpuscular volume-79 fl, Mean corpuscular
haemoglobin-24.9 pg, Mean corpuscular haemoglobin
concentration-31.2%, Liver function tests-within normal
limits, Renal function tests-within normal limits, Serum
proteins-within  normal limits, Serum iron-86microgm/
dl, Total iron binding capacity-321 microgram/dl,
Sickling test–negative, Haemoglobin electrophoresis-
Fetal haemoglobin-8.7%, Hemoglobin A2-4.30%,
Ultrasonography abdo-pelvis revealed massive
spleenomegaly and moderate hepatomegaly.
Discussion:
Beta thalassemia is a heterogenous disorder of the beta
globin chain. Most cases are autosomal recessive, but
dominant pattern of inheritance  exist. Beta thalassemia
major is also known as Cooley’s anaemia. There is
absence of  beta globin chain production whereas alpha
chain synthesis is maintained. There is erythrocyte
hemolysis and ineffective erythropoiesis. If untreated,
life expectancy of an individual is approximately six
years. If these individuals survive, they are prone for
iron toxicity like cardiac and hepatic dysfunction and
endocrinopathies like diabetes mellitus, hypothyroidism,
hypoparathyroidism, and women are likely to be infertile
due to gonadal dysfunction.[2]
With improved facilities and treatment, many women
are reaching to child bearing age. These women are
prone for pregnancy complications like pre-eclampsia,
preterm labour, fetal growth restriction and open neural
tube defects.
Worsening of anaemia occurs during gestation and
requires intensification of the transfusion and surveillance
regimen. Once or twice weekly antepartum testing can
be initiated at 28-32 weeks of gestation depending on
maternal and fetal status. Pre-conceptional or early
prenatal care should include a thorough physical
assessment of cardiac, liver and spleenic abnormalities.
Laboratory studies including evaluation of complete
blood count, platelets, ferritin, electrolytes, calcium,
partial thromboplastin time, total protein, albumin, liver
function and renal function should be done. Repeat
complete blood count every two weekly and ferritin
monthly is suggested. Liver function, renal function,
thyroid function and electrolytes should be repeated in
each trimester. Cases of beta-thalassemia major should
receive 5 mg folic acid per day. Iron supplementation
should be avoided.
Most patients with transfusion dependant beta-
thalassemia major are on a regimen of iron chelation
therapy with a goal to maintain serum ferritin levels
below 1300ng/ml. Chelation therapy is often
discontinued before or during early pregnancy due to
unknown teratogenic risks in pregnancy.[3]
Women with beta-thalassemia major often have skeletal
abnormalities and small stature due to marrow
expansion and hypermetabolism. There is increased risk
of cephalopelvic disproportion requiring elective
caesarean section.
Thalassemia trait patients do well, and generally have
no greater maternal and  fetal mortality though theyBangal V et al, Recurrent pregnancy loss..... Pravara Med Rev 2009; 4(1)
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sometimes require blood transfusion to relieve
symptoms or when the Hb appears to drop down below
8 gm%.[4]
 As transfusion and chelation improves the physical
condition of these women, vaginal delivery becomes
more likely to be successful. Regional epidural
anesthesia is preferred during vaginal delivery for pain
relief.
During postpartum period, birth control needs should
be addressed and unplanned pregnancies should be
discouraged. Estrogen containing oral pills are
contraindicated for fear of thrombo embolism in women
who have undergone  splenectomy.
Successful pregnancies are reported in women after
bone marrow transplantation. Stem cells derived from
fetal cord blood or fetal liver have been successfully
used for transplantation.
Pre-conceptional councelling: Father of the fetus is
adviced hemoglobin electrophoresis (if Mean
corpuscular volume is low). When father is having
normal hemoglobin, fetus has a 50% chance of beta-
thalassemia minor and 25% chance of normal
hemoglobin. When father is beta-thalassemia minor, the
risk of fetus being beta-thalassemia major is 50%.
Prenatal diagnosis can be made with chorion villous
sampling[5,6]. Pre-implantation blastomere biopsy and
DNA study is possible to select unaffected embryos
during in-vitro fertilization[7].
Elegance of molecular biology and modern concepts
of management of these  high risk  pregnancies  have
considerably brightened the prognosis over the last two
decades.[8]
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